ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO946

Kidney Transplant Candidates with Reduced Ejection Fraction: Risky Business or Not?

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Authors

  • Won, Alice H., Weill Cornell Medicine, New York, New York, United States
  • Kelkar, Ashwin, Weill Cornell Medicine, New York, New York, United States
  • Karas, Maria, Weill Cornell Medicine, New York, New York, United States
  • Dadhania, Darshana M., Weill Cornell Medicine, New York, New York, United States

Group or Team Name

  • New York Presbyterian-Weill Cornell Medicine.
Background

Heart failure with reduced ejection fraction (HFrEF) is prevalent among patients with advanced chronic kidney disease. Data remains limited on whether HFrEF at the time of transplant is associated with an increased risk of graft failure and mortality. In this study, we sought to compare the patient and graft survival between the cohorts of patients with or without HFrEF undergoing kidney transplantation (KTx).

Methods

In this retrospective case-control study, we performed a 1:2 matched cohort analysis of 103 KTx patients with pre-transplant EF ≤45% (HF cohort) and 206 patients with EF >45% (control cohort), transplanted between January 2011 - December 2021. Two cohorts were matched based on age, sex, donor type, and transplant year. Simultaneous liver-kidney transplants were excluded.

Results

Baseline characteristics were similar except pre-emptive transplant and thymoglobulin induction were less frequent in the HF cohort. Despite increased delayed graft function (DGF) in the HF cohort, there was no statistically significant difference in the mean creatinine levels at 3-months (1.51 vs. 1.56) and 1-year (1.41 vs. 1.57) post-KTx between the control and HF cohorts (Table 1). At a mean follow-up period of 4.7 years, the two cohorts demonstrated similar overall graft survival and patient survival (Figure 1), with no statistically significant difference in the rates of graft loss due to acute rejection or death due to cardiovascular cause (Table 1).

Conclusion

In our investigation, the graft and patient survival of control and HF cohorts were similar and comparable to the published ten-year KTx outcomes (PMID:26285695). Our data suggests low EF alone should not be a contraindication to KTx and is associated with acceptable long-term survival.